Prime Medicine Announces Closing of Upsized Initial Public Offering

Rhea-AI Summary

Prime Medicine, Inc. (Nasdaq: PRME) has successfully completed its upsized initial public offering, issuing 10,294,118 shares at $17.00 each, raising approximately $175 million before expenses. The underwriters also hold a 30-day option to purchase an additional 1,544,117 shares. Shares started trading on Nasdaq on October 20, 2022. This offering aims to fund the development of Prime Editing technology, which has the potential to address a wide range of genetic diseases by correcting mutations.

Positive

• Raised approximately $175 million from the IPO.
• Potential for Prime Editing technology to address around 90% of known genetic mutations.

Negative

• Risks inherent in biopharmaceutical development and clinical trials could affect future outcomes.

CAMBRIDGE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $175.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Prime Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 shares of its common stock at the initial public offering price less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on October 20, 2022 under the ticker symbol “PRME.” All shares in the offering were offered by Prime Medicine.

J.P. Morgan, Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 19, 2022. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (866) 803-9204 or by email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, or via email: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2^nd Floor, New York, New York 10014, by telephone at (866) 718-1649 or by e-mail to prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Prime Medicine

Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Prime Medicine’s expectations regarding the potential exercise of the underwriters 30-day option to purchase additional shares and Prime Editing’s therapeutic potential. Forward-looking statements are based on Prime Medicine’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development and clinical trials. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Prime Medicine undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information on this page as current or accurate after its publication date.

Media Contact:
Dan Budwick
1AB
dan@1ABmedia.com

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations
hannah.deresiewicz@sternir.com

FAQ

What was the price and size of Prime Medicine's IPO on October 24, 2022?

Prime Medicine's IPO consisted of 10,294,118 shares priced at $17.00 each, raising approximately $175 million.

What is the ticker symbol for Prime Medicine?

Prime Medicine trades under the ticker symbol 'PRME' on the Nasdaq.

What are the potential uses of the funds raised from the IPO?

The funds are intended to support the development of Prime Editing technology for addressing genetic diseases.

What options do underwriters have after Prime Medicine's IPO?

Underwriters have a 30-day option to purchase up to an additional 1,544,117 shares at the IPO price.

What are the risks associated with Prime Medicine's business?

Risks include uncertainties related to biopharmaceutical product development and clinical trials.